FDA 483 - K.C. Pharmaceuticals, Inc. - February 13, 2023

The content of the FDA 483 document, specifically pages 18 through 27, was not provided. As such, it is impossible to generate a concise summary detailing the company name, inspection dates, main violations/issues, regulatory framework, or required actions as requested. Please provide the full text of the document to enable accurate summarization.